article thumbnail

Amid FTC crackdown, judge says Teva inhaler patents are 'improperly listed' in FDA Orange Book

Fierce Pharma

A federal judge in New Jersey ruled that five of Teva’s patents on the metered dose inhaler for its asthma med ProAir HFA are “improperly listed” in the FDA’s Orange Book. The ruling came in Teva's case against Amneal Pharmaceuticals, which is seeking to launch a generic version of the drug.

FDA 271
article thumbnail

Solv launches new same-day appointment booking with Carbon Health as customer

MedCity News

Solv has added direct real-time booking to Solv Connect, its marketplace for same-day and next-day healthcare appointments. This announcement decouples Solv Connect from the company’s other software offering, Solv Experience, which is its practice management platform.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sanofi lays out €40M to beef up transplant, diabetes drug production in France

Fierce Pharma

With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in a bid to boost production for a long-approved transplant treatment and a | Sanofi has unveiled a 40 million euro investment at its Lyon Gerland biomanufacturing site in France.

article thumbnail

FTC Sees Red Over Alleged Misuse of FDA Orange Book, Puts 10 Pharmas on Notice

MedCity News

The Federal Trade Commission says more than 100 patents from 10 biopharma companies are improperly listed in the FDA’s official publication of approved products. Such listings delay generic competition, which reduces consumer choice and keeps prices high, the regulator said.

Biopharma 337
article thumbnail

The GTM Intelligence Era: ZoomInfo 2025 Customer Impact Report

Revenue teams using our Go-To-Market Intelligence platform grew pipeline by 32%, increased deal sizes by 40%, and booked 55% more meetings. ZoomInfo customers aren’t just selling — they’re winning. Download this report to see what 11,000+ customers say about our Go-To-Market Intelligence platform and how it impacts their bottom line.

article thumbnail

CDMO Samsung Biologics bags $1.2B production contract, bringing total 2024 deal value to $3.3B+

Fierce Pharma

With multiple high-profile production pacts already in the books for 2024, CDMO Samsung Biologics has hooked another big one. Following a string of high-profile deals, Samsung Biologics has locked down a $1.2 billion contract with an unnamed Asia-based pharmaceutical company that’s expected to run through December 2037.

article thumbnail

Read to lead: 6 books pharma execs swear by

PharmaVoice

From an epic, alternative reality fantasy to a ‘biography of cancer,’ these six reads have stuck with pharma execs as they navigate how to lead.

Leads 265